Pozniak AL - Search Results

1

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.

Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group. Pozniak AL, et al. AIDS. 2010 Jan 2;24(1):55-65. doi: 10.1097/QAD.0b013e32833032ed. AIDS. 2010. PMID: 19926964 Clinical Trial.

2

Summary of track B: clinical science.

De Cock KM, Churchill D, Grant A, Del Amo J, Rouleau D, Zala C, Harris M, Pozniak A, Williams I. De Cock KM, et al. AIDS. 1996 Dec;10 Suppl 3:S107-13. AIDS. 1996. PMID: 8970717 Review.

3

Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. National Prospective Monitoring System Steering Group.

Beck EJ, Mandalia S, Williams I, Power A, Newson R, Molesworth A, Barlow D, Easterbrook P, Fisher M, Innes J, Kinghorn G, Mandel B, Pozniak A, Tang A, Tomlinson D. Beck EJ, et al. AIDS. 1999 Oct 22;13(15):2157-64. doi: 10.1097/00002030-199910220-00020. AIDS. 1999. PMID: 10546870

4

Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine.

Sabin CA, Fisher M, Churchill D, Pozniak A, Hay P, Easterbrook P, Williams I. Sabin CA, et al. J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):462-5. doi: 10.1097/00126334-200104150-00009. J Acquir Immune Defic Syndr. 2001. PMID: 11391166 Clinical Trial.

5

Continuing HIV therapy in the ICU.

Soni N, Pozniak A. Soni N, et al. Crit Care. 2001 Oct;5(5):247-8. doi: 10.1186/cc1040. Epub 2001 Sep 13. Crit Care. 2001. PMID: 11737898 Free PMC article.

6

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL. Dean GL, et al. Among authors: pozniak al. AIDS. 2002 Jan 4;16(1):75-83. doi: 10.1097/00002030-200201040-00010. AIDS. 2002. PMID: 11741165

7

The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients.

Gilleece Y, Torti C, Mandalia S, Gazzard BG, Pillay D, Pozniak AL. Gilleece Y, et al. Among authors: pozniak al. HIV Med. 2003 Oct;4(4):305-10. doi: 10.1046/j.1468-1293.2003.00163.x. HIV Med. 2003. PMID: 14525540 Free article.

8

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.

Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, De Dier K, Peeters M, Woodfall B, Stebbing J, vant' Klooster GA. Gazzard BG, et al. Among authors: pozniak al. AIDS. 2003 Dec 5;17(18):F49-54. doi: 10.1097/00002030-200312050-00001. AIDS. 2003. PMID: 14685068

9

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

Boffito M, Kurowski M, Kruse G, Hill A, Benzie AA, Nelson MR, Moyle GJ, Gazzard BG, Pozniak AL. Boffito M, et al. Among authors: pozniak al. AIDS. 2004 Jun 18;18(9):1291-7. doi: 10.1097/00002030-200406180-00007. AIDS. 2004. PMID: 15362661

10

The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.

Sproat M, Pozniak AL, Peeters M, Winters B, Hoetelmans R, Graham NM, Gazzard BG. Sproat M, et al. Among authors: pozniak al. Antivir Ther. 2005;10(2):357-61. Antivir Ther. 2005. PMID: 15865231

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

450 results

Search Page

Filters